South Korea's bio-venture company GI Innovation has registered GI-301, an allergy treatment drug, and a microbiome-based combination therapy, at the European Patent Office. Through patent registration, the company can prevent other pharmaceutical firms from commercializing the microbiome by incorporating it into a fusion protein in Europe. GI-301 is a fusion protein capable of effectively handling allergic reactions with its Immunoglobulin E (IgE), a type of antibody that travels to cells. Because IgE overreacts to an allergen by producing antibodies, it can cause severe allergic diseases such as asthma and atopic dermatitis. According to GI Innovation CEO Rhee Byung-geon, GI-301 showed about 70 times higher lgE binding power than other competitive drugs and significant blood lgE reduction effect only with a single administration. https://www.ajudaily.com/view/20230727165321750

GI Innovation expressed its intention to pursue a license out deal for GI-301, an allergy treatment, with Japanese companies at a press conference at the Grand InterContinental Seoul Parnas Hotel, in southern Seoul, on Monday. "We are currently in talks with three Japanese pharmaceutical companies to transfer technology for GI-301, and we will finalize the transfer within this year," said GI Innovation CEO and Chairman Rhee Byung-gun.https://www.koreabiomed.com/news/articleView.html?idxno=21609

SEOUL -- South Korea's bio-venture company GI Innovation will adopt a new production process for the company's immune-oncology candidate substance called "GI-101." GI-101 is a dual fusion protein with the functions of CD80 and IL-2, proteins that play important roles in the immune system. Through a joint clinical trial with global pharmaceutical companies including America's MSD and Britain's AstraZeneca, the first patient treatment was launched in February 2023. According to the bio-venture on April 10, GI-101 produced through the new production process can increase the proliferation of anti-cancer immune cells in monkey models by about three times compared to the agent created through the existing process. https://www.ajudaily.com/view/20230410165240775

GI Innovation outlined ambitious plans to transfer at least five additional technologies within the next five years at its initial public offering (IPO) briefing session at the Conrad Hotel in Yeouido, Seoul, Monday.Established as a bio-venture in 2017, GI Innovation researches and develops next-generation immunotherapy drugs based on dual fusion proteins. The company's major pipelines include dual fusion immuno-cancer drugs GI-101 and GI-102, and allergy treatment GI-301 which are in clinical trials alongside other preclinical drug candidates GI-104, GI-108, and GI-305.https://www.koreabiomed.com/news/articleView.html?idxno=20640

GI Innovation said Thursday that it has won approval in the preliminary screening to be listed on the Kosdaq market from the Korea Exchange (KRX). The approval came eight months after the company applied for a preliminary review in April. Read More

Preliminary results of GII-101-P101 (Keynote-B59): GI-101 (CD80-IgG4 Fc-IL2v) as a single agent and in combination with pembrolizumab in patients with advanced and/or metastatic solid tumors

Local drug developer GI Innovation said Thursday its Merkel cell cancer drug GI-101, used to treat a rare type of skin cancer, has received orphan drug designation from the United States Food and Drug Administration.The designation is given to drugs that treat rare diseases that affect less than 100,000 people. The status gives tax cuts during clinical trials, and waives certain restrictions and fees. It also allows market monopolization for seven years after the drug is launched.Merkel cell cancer appears between the dermis and epidermis of the skin and mostly affects those over 50. The five-year survival rate is less than 20 percent.GI Innovation said it hopes the designation will accelerate clinical trials for its Merkel cell cancer drug. Read More

SEOUL -- A material patent for GI-301, an allergy treatment drug candidate developed by South Korea's bio-venture company GI Innovation, has been registered in Japan where pollen allergy diseases are widespread. The company would try to accelerate technology transfer to Japanese pharmaceutical companies.GI-301 is a biologic for the treatment of allergic diseases, including atopic dermatitis and chronic idiopathic. Yuhan, a pharmaceutical and chemical company in South Korea, signed a contract worth some 20 billion won ($15 million) in 2020 to co-develop and sell GI-301 in overseas markets except for Japan. Read More

GI-101, an immunotherapy agent being developed by South Korea's bio-venture company GI Innovation, has been selected for a government-initiated drug development program to receive financial support at clinical stages. GI Innovation said it would get up to seven billion won ($5.5 million) in research support for two years from the Korea Drug Development Fund (KDDF), which supports the investment, nurture and development of promising drugs. KDDF's move is seen as a symbolic recognition of GI Innovation's technological prowess. Read More

Local drug developer GI Innovation has submitted a preliminary application for listing on the country’s secondary tech-heavy bourse Kosdaq with its eyes set on going public in the second half of the year, the company said Thursday.GI Innovation’s initial public offering will be carried out under Kosdaq’s special listing track, known as the “unicorn special listing.”The Korea Exchange established the unicorn special listing process in April last year to simplify the technological evaluation process for companies with excellent market evaluation. Read More

GI Innovation, an innovative new drug development company, announced on February 23 that it has signed a biomarker joint research MoU with CellKey, a Glycoprotein biomarker development company, to develop next-generation innovative immuno-oncology. GI Innovation signed MoU with CellKey for biomarker joint research to develop next-generation innovative immuno-oncology. (from left) Ji-Soo Kim director, Na-Ri Yun VP, Myoung-Ho Jang Chairman of GI Innovation and Nam-Yong Lee CEO, Sang-Yong Lee COO, Kwang-Hoe Kim Head of Bio-R&D center of CellKey participated in the MoU ceremony. Under the MoU, GI Innovation will progress joint biomarker research to develop next-generation protein and antibody drugs using GI Innovation’s bispecific fusion protein development platform GI-SMART™ and CellKey’s AI-powered biomarker discovery platform SpAC9 Pipeline. Read More

GI Innovation said it has entered into a partnership with GI Cell and Yonsei University Health System (YUHS) to establish a cell therapy center for advanced biopharmaceuticals.Under the accord, GI Innovation and GI Cell will increase the production capability of advanced biopharmaceuticals with YUHS by establishing good manufacturing practice (GMP) facilities in Severance Hospital and Songdo Severance Hospital under construction. Read More